Biosimilars

What are biosimilars? The Pharmacy Times® Biosimilars resource center keeps those in the space up to date with the latest clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
 

What can we help you find?
[[thumbnail_alt_text]]
Pharmacists Play Key Role in Driving Utilization of Oncology Biosimilars
As biosimilar development continues to grow, pharmacists will be essential in transitioning both clinicians and patients alike in the use of these therapies.
[[thumbnail_alt_text]]
How Can Pharmacists Approach Reimbursement Challenges to Improve Biosimilar Use?
At the 2018 ASHP Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, offered advice on how pharmacy providers can work to overcome biosimilar reimbursement challenges and encourage biosimilar adoption.
[[thumbnail_alt_text]]
Phase 3 Studies Show Efficacy of Sandoz Biosimilars Adalimumab, Etanercept
Biosimilars adalimumab and etanercept showed equivalent safety and efficacy to reference products in patients with rheumatoid arthritis.
[[thumbnail_alt_text]]
Biosimilars Action Plan: There's No Better Time Than Now
Several hurdles remain for biosimilars to flourish in the US market.
[[thumbnail_alt_text]]
Innovations and New Approaches for Biological Drugs
Presenters delved into the topic of biological drugs and gene therapy during the recent International Pharmaceutical Federation (FIP) World Congress in Glasgow Scotland.
[[thumbnail_alt_text]]
How Could Biosimilars Change the Specialty Drug Landscape?
Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses biosimilars and the potential impact on patient care.
[[thumbnail_alt_text]]
FDA Biosimilar Plan Offers Employers Saving Strategy Solution
Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.
[[thumbnail_alt_text]]
Buying In on Biosimilars
With drugs that achieve similar clinical outcomes, it will ultimately come down to financial differentiation that can determine which drugs lead the market.
[[thumbnail_alt_text]]
A Case for Biosimilar Use: 5 Things You Need to Know
Biosimilars are a potential solution to the ever-growing problem of high specialty drug costs.
[[thumbnail_alt_text]]
FDA Biosimilar Video Series Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
[[thumbnail_alt_text]]
New FDA Policies to Help Generic, Biosimilar Drug Competition and Access
New policies that aim to help generic drug makers move their products through the development and approval processes more efficiently have been announced by FDA Commissioner Scott Gottlieb, MD.
[[thumbnail_alt_text]]
FDA Video Series Highlights Promise of Biosimilars
A new 5-part video series released by the FDA is part of a larger education and outreach effort about biosimilars and interchangeable products.

The Pharmacy Times® Biosimilars condition center provides a source of all the latest clinical information, with articles covering updates from the robust pipeline of biosimilars, and the newest data from all phases of clinical trials and studies. 

Among its other resources are a wealth of videos including interviews with thought leaders and experts in biosimilars, and moderated panel discussions about the best practices and key methods for treating complex cases, utilizing the newest biologic medical products replicating medical products originally manufactured by popular companies.